CA2173456A1 - Inhibitors of phosphoinositide-specific phospholipase c - Google Patents

Inhibitors of phosphoinositide-specific phospholipase c

Info

Publication number
CA2173456A1
CA2173456A1 CA002173456A CA2173456A CA2173456A1 CA 2173456 A1 CA2173456 A1 CA 2173456A1 CA 002173456 A CA002173456 A CA 002173456A CA 2173456 A CA2173456 A CA 2173456A CA 2173456 A1 CA2173456 A1 CA 2173456A1
Authority
CA
Canada
Prior art keywords
hydrogen
plc
glu
leu
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002173456A
Other languages
English (en)
French (fr)
Inventor
Jackson B. Gibbs
Kenneth S. Koblan
Angus M. Macleod
Kevin J. Merchant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2173456A1 publication Critical patent/CA2173456A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002173456A 1993-10-15 1994-10-11 Inhibitors of phosphoinositide-specific phospholipase c Abandoned CA2173456A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/138,133 US5519163A (en) 1993-10-15 1993-10-15 Inhibitors of phosphoinositide-specific phospholipase C
US138,133 1993-10-15

Publications (1)

Publication Number Publication Date
CA2173456A1 true CA2173456A1 (en) 1995-04-20

Family

ID=22480566

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002173456A Abandoned CA2173456A1 (en) 1993-10-15 1994-10-11 Inhibitors of phosphoinositide-specific phospholipase c

Country Status (6)

Country Link
US (1) US5519163A (en:Method)
EP (1) EP0746323A1 (en:Method)
JP (1) JPH09505033A (en:Method)
AU (1) AU696622B2 (en:Method)
CA (1) CA2173456A1 (en:Method)
WO (1) WO1995010286A1 (en:Method)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379235B1 (en) 2000-10-10 2006-12-20 University Of North Carolina At Chapel Hill Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers
US20020107193A1 (en) * 2000-11-09 2002-08-08 Glazner Gordon W. Therapeutic uses for IP3 receptor-mediated calcium channel modulators
US20060128667A1 (en) * 2002-05-11 2006-06-15 Montes Imber F Hydroxyphosphonates and phosphonophosphates as apolipoprotein e modulators
AU2006249350B2 (en) 2003-11-19 2012-02-16 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
BRPI0416639A (pt) * 2003-11-19 2007-01-16 Metabasis Therapeutics Inc tiromiméticos contendo fósforo
EP1566447A1 (en) * 2004-02-20 2005-08-24 Aventis Pharma Deutschland GmbH Glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C regulation
CN101378656A (zh) * 2005-06-07 2009-03-04 加利福尼亚大学董事会 为治疗疼痛对EPAC、磷脂酶Cε和磷脂酶D的抑制
WO2013138684A1 (en) * 2012-03-15 2013-09-19 Montana Molecular Llc Genetically encoded fluorescent sensors for detecting intracellular signalling through diacylglycerol pathways
WO2015066706A2 (en) 2013-11-04 2015-05-07 Montana Molecular Llc GENETICALLY ENCODED FLUORESCENT SENSORS FOR DETECTING LIGAND BIAS AND INTRACELLULAR SIGNALING THROUGH cAMP PATHWAYS
CN110198719A (zh) 2016-11-21 2019-09-03 维京治疗公司 治疗糖原贮积病的方法
KR102600115B1 (ko) 2017-06-05 2023-11-09 바이킹 테라퓨틱스 인코포레이티드 섬유증 치료를 위한 조성물
AU2019238090B2 (en) 2018-03-22 2024-08-01 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
CN109516623B (zh) * 2018-11-16 2021-06-01 浙江万盛股份有限公司 一种三丁氧乙基磷酸酯废水的综合利用方法
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474806A (en) * 1982-05-10 1984-10-02 Merck & Co., Inc. Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents

Also Published As

Publication number Publication date
US5519163A (en) 1996-05-21
AU696622B2 (en) 1998-09-17
AU7973894A (en) 1995-05-04
JPH09505033A (ja) 1997-05-20
EP0746323A1 (en) 1996-12-11
EP0746323A4 (en:Method) 1997-01-22
WO1995010286A1 (en) 1995-04-20

Similar Documents

Publication Publication Date Title
AU696622B2 (en) Inhibitors of phosphoinositide-specific phospholipase C
JP4102445B2 (ja) 脂肪酸アミドヒドロラーゼ
US5593878A (en) Recombinant phospholipase A2 enzyme
CN1313472C (zh) Hiv蛋白酶抑制剂化合物的膦酸酯类似物的细胞蓄积及这类化合物
KR100332273B1 (ko) 엔-(아로일)글리신하이드록삼산유도체및이와관련된화합물
US5994503A (en) Nucleotide and protein sequences of lats genes and methods based thereon
US20080076141A1 (en) Novel murine and human kinases
US5554511A (en) Calcium independent cytosolic phospholipase A2 /B enzymes
JP2002515020A (ja) ＴＮＦ−α転換酵素
EP0244189A2 (en) Human pancreatic elastase I
WO2006011485A1 (ja) アミロイドペプチドの凝集を抑制する蛋白質とその作用
EA006874B1 (ru) Полипептид, обладающий активностью rap [белка, ассоциированного с rip (взаимодействующим с рецептором белком)], кодирующая его последовательность днк и способы их получения и использования
US5474921A (en) Expression and purification of phosphoinositide-specific phospholipase C-γ
JPH08504602A (ja) Ｔｉａ−１結合タンパク質及びそれをコードする分離された相補的ｄｎａ
US6812017B2 (en) Mammalian secreted group IIF phospholipase A2
IVANOV et al. ω-Oxidation impairs oxidizability of polyenoic fatty acids by 15-lipoxygenases: consequences for substrate orientation at the active site
JP2003502006A (ja) Ｉｌ−１７ｒｈｄｎａ及びポリペプチド
JP2002524048A (ja) キナーゼ機能を有するポリペプチドをコードするヒトｃＤＮＡ
JPH07258132A (ja) 新規ヒドロキノン化合物
WO2000052043A1 (en) Polypeptide having antihuman immunodeficiency virus activity, gene encoding the polypeptide and process for producing the polypeptide
RU2073000C1 (ru) Производные гризеоловой кислоты или их фармацевтически приемлемые соли или их сложные эфиры (варианты)
JP2002537814A (ja) ヒスチジン・プロテイン・ホスファターゼ
JP2002524046A (ja) キナーゼ作用を有するポリペプチドをコードするマウスｄｎａ分子
AU664752B2 (en) Receptor-type tyrosine kinase-like molecules
US6894166B2 (en) Dichlorinated heterocyclic compounds and methods of synthesis

Legal Events

Date Code Title Description
FZDE Discontinued